Rosiglitzone suppresses angiotensin II-induced production of KLF5 and Cell proliferation in rat vascular smooth muscle cells

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Gao, Dengfeng ^a   Hao, Guanghua ^a   Meng, Zhe ^a   Ning, Ning ^a   Yang, Guang ^a   Liu, Zhongwei ^a   Dong, Xin ^a   Niu, Xiaolin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITROBENZANILIDE; 4,4' ISOPROPYLIDENEDIPHENOL; ANGIOTENSIN II; CYCLIN D1; DELTA12 PROSTAGLANDIN J2; EARLY GROWTH RESPONSE FACTOR; KRUPPEL LIKE FACTOR 5; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN KINASE C ZETA; ROSIGLITAZONE; SMALL INTERFERING RNA; 15-DEOXYPROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTIDIABETIC AGENT; KLF5 PROTEIN, RAT; KRUPPEL LIKE FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN D2; PROTEIN KINASE C; PROTEIN KINASE C ETA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; AORTA; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; MALE; MOLECULAR INTERACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; BODY WEIGHT; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

RATTUS;

ANGIOTENSIN II; ANILIDES; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN D1; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PPAR GAMMA; PROSTAGLANDIN D2; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84928819948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123724     Document Type: Article

References (47)

1. Rizzoni D, Muiesan ML, Porteri E, De Ciuceis C, Boari GE, Salvetti M, et al. Vascular remodeling, macro- and microvessels: therapeutic implications. Blood Press. 2009; 18:242-246. doi: 10.3109/08037050903254923 PMID: 19919394
2. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res. 2007; 101:441-454. PMID: 17761934
3. Dong JT, Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci. 2009; 66:2691-2706. doi: 10.1007/s00018-009-0045-z PMID: 19448973
4. Watanabe N, Kurabayashi M, Shimomura Y, Kawai-Kowase K, Hoshino Y, Manabe I, et al. BTEB2, a Kruppel-like transcription factor, regulates expression of the SMemb/Nonmuscle myosin heavy chain B (SMemb/NMHC-B) gene. Circ Res. 1999; 85:182-191. PMID: 10417400
5. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, Miyamoto S, et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med. 2002; 8:856-863. PMID: 12101409
6. Nagai R, Shindo T, Manabe I, Suzuki T, Kurabayashi M. KLF5/BTEB2, a Kruppel-like zinc-finger type transcription factor, mediates both smooth muscle cell activation and cardiac hypertrophy. Adv Exp Med Biol. 2003; 538:57-65; discussion 66. PMID: 15098654
7. Suzuki T, Aizawa K, Matsumura T, Nagai R. Vascular implications of the Kruppel-like family of transcription factors. Arterioscler Thromb Vasc Biol. 2005; 25:1135-1141. PMID: 15817882
8. Nagai R, Suzuki T, Aizawa K, Shindo T, Manabe I. Significance of the transcription factor KLF5 in cardiovascular remodeling. J Thromb Haemost. 2005; 3:1569-1576. PMID: 16102021
9. Bafford R, Sui XX, Wang G, Conte M. Angiotensin II and tumor necrosis factor-alpha upregulate survivin and Kruppel-like factor 5 in smooth muscle cells: Potential relevance to vein graft hyperplasia. Surgery. 2006; 140:289-296. PMID: 16904982
10. Gao D, Niu X, Ning N, Hao G. Regulation of angiotensin II-Induced Kruppel-like factor 5 expression in vascular smooth muscle cells. Biol Pharm Bull. 2006; 29:2004-2008. PMID: 17015941
11. Suzuki T, Sawaki D, Aizawa K, Munemasa Y, Matsumura T, Ishida J, et al. Kruppel-like factor 5 shows proliferation-specific roles in vascular remodeling, direct stimulation of cell growth, and inhibition of apoptosis. J Biol Chem. 2009; 284:9549-9557. doi: 10.1074/jbc.M806230200 PMID: 19189969
12. Liu Y, Wen JK, Dong LH, Zheng B, Han M. Kruppel-like factor (KLF) 5 mediates cyclin D1 expression and cell proliferation via interaction with c-Jun in Ang II-induced VSMCs. Acta Pharmacol Sin. 2010; 31:10-18. doi: 10.1038/aps.2009.185 PMID: 20037604
13. Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys. 2000; 32 Spring:187-204. PMID: 11330046
14. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005; 54:2460-2470. PMID: 16046315
15. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992; 68:879-887. PMID: 1312391
16. Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR-gamma on vascular endothelial function. Biochem Biophys Res Commun. 1999; 254:757-763. PMID: 9920814
17. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPAR-gamma in rat and human vascular smooth muscle cells. Circulation. 2000; 101:1311-1318. PMID: 10725292
18. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-alpha and-gamma in blood vessels of spontaneously hypertensive rats. Hypertension. 2001; 38:249-254. PMID: 11509485
19. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998; 391:79-82. PMID: 9422508
20. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and-gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003; 23:45-51. PMID: 12524223
21. de Oliveira Silva-Junior G, da Silva Torres T, de Souza Mendonca L, Alberto Mandarim-de-Lacerda C. Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats. Exp Toxicol Pathol. 2009.
22. Qin HD, Huang D, Weng XD, Xu F. Upregulation of peroxisome proliferator-activated receptor-gamma and NADPH oxidases are involved in restenosis after balloon injury. J Cell Physiol. 2009; 221:387-393. doi: 10.1002/jcp.21865 PMID: 19562688
23. Gizard F, Bruemmer D. Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases. PPAR Res. 2008; 2008:429123. doi: 10.1155/2008/429123 PMID: 18288288
24. Li J, Wang N. Peroxisome proliferator-activated receptor-gamma in vascular biology. Cardiovasc Hematol Disord Drug Targets. 2007; 7:109-117. PMID: 17584045
25. Gao DF, Niu XL, Hao GH, Peng N, Wei J, Ning N, et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol. 2007; 73:185-197. PMID: 17074304
26. Chang S, Chen W, Yang J. Another formula for calculating the gene change rate in real-time RT-PCR. Mol Biol Rep. 2009; 36:2165-2168. doi: 10.1007/s11033-008-9430-1 PMID: 19109763
27. Liu Y, Tian XY, Mao G, Fang X, Fung ML, Shyy JY, et al. Peroxisome proliferator-activated receptor-gamma ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor. Hypertension. 2012; 60:1471-1478. doi: 10.1161/HYPERTENSIONAHA.112.198887 PMID: 23108648
28. Fujiu K, Manabe I, Ishihara A, Oishi Y, Iwata H, Nishimura G, et al. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ Res. 2005; 97:1132-1141. PMID: 16224062
29. He M, Han M, Zheng B, Shu YN, Wen JK. Angiotensin II stimulates KLF5 phosphorylation and its interaction with c-Jun leading to suppression of p21 expression in vascular smooth muscle cells. J Biochem. 2009; 146:683-691. doi: 10.1093/jb/mvp115 PMID: 19628677
30. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology. 2001; 142:3125-3134. PMID: 11416035
31. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000; 102:1834-1839. PMID: 11023940
32. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Sato K, et al. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertens Res. 2001; 24:229-233. PMID: 11409645
33. Fukumoto S, Nishizawa Y, Hosoi M, Koyama H, Yamakawa K, Ohno S, et al. Protein kinase C delta inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression. J Biol Chem. 1997; 272:13816-13822. PMID: 9153238
34. Gruber JR, Ohno S, Niles RM. Increased expression of protein kinase C alpha plays a key role in retinoic acid-induced melanoma differentiation. J Biol Chem. 1992; 267:13356-13360. PMID: 1618838
35. Han EK, Cacace AM, Sgambato A, Weinstein IB. Altered expression of cyclins and c-fos in R6 cells that overproduce PKC epsilon. Carcinogenesis. 1995; 16:2423-2428. PMID: 7586146
36. Liao DF, Monia B, Dean N, Berk BC. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem. 1997; 272:6146-6150. PMID: 9045626
37. Verrier E, Wang L, Wadham C, Albanese N, Hahn C, Gamble JR, et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res. 2004; 94:1515-1522. PMID: 15117825
38. Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells. J Biol Chem. 2001; 276:47650-47657. PMID: 11598137
39. Whiteside C, Wang H, Xia L, Munk S, Goldberg HJ, Fantus IG. Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells. Exp Diabetes Res. 2009; 2009:910783. doi: 10.1155/2009/910783 PMID: 19609456
40. Isenovic ER, Kedees MH, Haidara MA, Trpkovic A, Mikhailidis DP, Marche P. Involvement of ERK1/2 kinase in insulin-and thrombin-stimulated vascular smooth muscle cell proliferation. Angiology. 2010; 61:357-364. doi: 10.1177/0003319709358693 PMID: 20304866
41. Bai YP, Liu YH, Chen J, Song T, You Y, Tang ZY, et al. Rosiglitazone attenuates NF-kappaB-dependent ICAM-1 and TNF-alpha production caused by homocysteine via inhibiting ERK1/2/p38MAPK activation. Biochem Biophys Res Commun. 2007; 360:20-26. PMID: 17583675
42. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, et al. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol. 2008; 28:718-724. doi: 10.1161/ATVBAHA.107.160713 PMID: 18239149
43. Ji Y, Liu J, Wang Z, Liu N, Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest. 2009; 89:887-902. doi: 10.1038/labinvest.2009.45 PMID: 19451898
44. Solini A, Santini E, Madec S, Nannipieri M, Bonotti A, Cuccato S, et al. Rosiglitazone increases matrix production and quenches inflammation: studies in human cells. Diabetes Metab Res Rev. 2008; 24:197-204. PMID: 17922475
45. Kim JS, Kim IK, Lee SY, Song BW, Cha MJ, Song H, et al. Anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway. Cell Biol Int. 2012; 36:305-310. doi: 10.1042/CBI20100524 PMID: 22050182
46. Wan H, Yuan Y, Liu J, Chen G. Pioglitazone, a PPAR-gamma activator, attenuates the severity of cerulein-induced acute pancreatitis by modulating early growth response-1 transcription factor. Transl Res. 2012; 160:153-161. doi: 10.1016/j.trsl.2012.02.003 PMID: 22677361
47. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol. 2009; 174:519-533. doi: 10.2353/ajpath.2009.080574 PMID: 19147827